OXFORD, England & STAMFORD, Conn., July 8, 2026
Caristo Diagnostics has announced that new clinical evidence supporting its AI-powered coronary inflammation and plaque analysis technologies will be showcased at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting 2026 in San Diego, reinforcing the growing scientific validation of AI-driven cardiovascular risk assessment. The presentations feature data generated from the University of Oxford-led Oxford Risk Factors and Non-Invasive Imaging (ORFAN) registry, one of the world’s largest studies evaluating coronary computed tomography angiography (CCTA) imaging biomarkers for predicting long-term cardiovascular outcomes. Notably, three of the six abstracts nominated for the prestigious SCCT Young Investigator Award utilize Caristo’s technologies, including the first-ever application of the company’s Fat Attenuation Index (FAI-Score™) on non-contrast cardiac CT imaging. The findings further strengthen the clinical evidence supporting Caristo’s CaRi-Heart® FAI-Score™ and CaRi-Plaque® technologies, which are designed to identify coronary inflammation, characterize plaque burden, and enable earlier detection of patients at increased risk of heart attack before symptoms develop. The company’s participation at SCCT 2026 highlights the expanding role of artificial intelligence in precision cardiovascular medicine and demonstrates continued progress toward improving preventive cardiology through advanced imaging analytics.
ORFAN Registry Data Reinforces AI-Powered Cardiovascular Risk Prediction
The scientific presentations highlight several important analyses from the ORFAN registry, demonstrating how AI-based coronary inflammation imaging and plaque quantification improve cardiovascular risk prediction beyond conventional assessment methods. One award-nominated study shows that FAI-Score measurements performed on both contrast and non-contrast cardiac CT scans significantly enhance cardiovascular risk stratification beyond coronary calcium scoring and plaque volume analysis, potentially expanding the clinical utility of AI-assisted cardiac imaging. Additional research demonstrates that FAI-Score provides prognostic value beyond established PREVENT cardiovascular risk models, while another large-scale investigation involving more than 80,000 patients found that AI-powered quantification of calcified and non-calcified coronary plaques accurately predicts cardiovascular events over a 10-year period.
These findings build upon previously published ORFAN registry results demonstrating that coronary inflammation measured using Fat Attenuation Index technology can identify patients at elevated cardiovascular risk years before clinical events occur. Collectively, the studies reinforce the growing body of evidence supporting AI-enabled imaging biomarkers as valuable tools for earlier diagnosis, personalized prevention, and improved clinical decision-making in cardiovascular disease management.
Caristo Expands Clinical Impact of AI-Based Coronary Imaging
Advertisement
Beyond the Young Investigator Award presentations, Caristo Diagnostics will participate in multiple scientific sessions focused on integrating AI-powered plaque analysis and coronary inflammation imaging into routine cardiovascular care. International cardiovascular experts will discuss how CaRi-Heart® FAI-Score™ and CaRi-Plaque® technologies can refine patient risk assessment, identify vulnerable individuals who may otherwise be classified as low risk, and support more personalized treatment strategies. Caristo’s AI technologies were developed from pioneering research at the University of Oxford and have gained increasing recognition for their ability to detect hidden heart disease before symptoms appear.
The company’s CaRi-Plaque® technology has received FDA clearance in the United States, while CaRi-Heart® is commercially available across Europe, the United Kingdom, Switzerland, and Australia, with investigational use continuing in the U.S. The expanding ORFAN registry is expected to include long-term clinical outcomes from up to 250,000 patients worldwide, further strengthening the evidence base supporting AI-enabled cardiovascular diagnostics. As artificial intelligence continues transforming medical imaging and precision medicine, Caristo Diagnostics is positioning its validated coronary inflammation and plaque analysis platform at the forefront of next-generation cardiovascular disease prevention, risk prediction, and personalized patient management.
Source: Caristo Diagnostics press release
